Venous thromboembolism in very elderly patients: Findings from a prospective registry (RIETE)

Haematologica

Volumn 91, Issue 8, 2006, Pages 1046-1051

  López Jiménez, Luciano ^a   Montero, Manuel ^a   González Fajardo, José Antonio ^b   Arcelus, Juan Ignacio ^c   Suárez, Carmen ^d   Lobo, José Luís ^e   Monreal, Manuel ^f  

^a Nephrology Service IMIBIC Hospital Universitario   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL TXAGORRITXU   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Bleeding complications; Elderly; Mortality; Pulmonary embolism; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; CORTICOSTEROID; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CAUSE OF DEATH; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; FETAL HEMORRHAGE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HUMAN; INCIDENCE; KIDNEY FUNCTION; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; RECURRENT DISEASE; REGISTER; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; SYMPTOM; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; SURVIVAL RATE; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33746999380     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic desease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:4015-285.
2. Culleton BF, Larson MG, Evans JC, Wilson PW, Barrett BJ, Parfrey PS, et al. Prevalence and correlates of elevated serum creatinine levels. The Framingham Heart Study. Arch Intern Med 1999;159:1785-90.
3. Grundy SM, Cleeman JI, Rifkind BM, Kuller LH, Cholesterol lowering in the elderly population. The Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med 1999;159:1670-8.
4. Van Gorp ECM, Brandjes DPM, ten Cate JW. Rational antithrombotic therapy and prophylaxis in elderly, immobile patients. Drug Therapy 1998;13:145-57.
5. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-52.
6. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119:108S-21S.
7. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 1993;95:315-28.
8. White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999;107:414-24.
9. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995;70:725-33.
10. Fihn SD, McDonnel M, Martin D. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993;118:511-20.
11. Arcelus JI, Monreal M, Caprini JA, Suárez C, González- Fajardo JA. The management and outcome of acute venous thromboembolism: a prospective registry including 4011 Patients. The RIETE investigators. J Vasc Surg 2003;38:916-22.
12. Monreal M, Kakkar AK, Caprini JA, Barba R, Uresandi F, Valle R, et al. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE Registry. The RIETE Investigators. J Thromb Haemost 2004;2:1-7.
13. Monreal M, Suárez C, González-Fajardo JA, Barba R, Uresandi F, Valle R, et al. Management of patients with acute venous thromboembolism: findings from the RIETE Registry. The RIETE investigators. J Pathophysiol Haemost Thromb 2004;33:330-4.
14. Nieto JA, Díaz de Tuesta A, Marchena PJ, Tiberio G, Todolí JA, Samperiz AL, et al. Clinical outcome of patients with venous thromboembolism and recent major bleeding: Findings from a prospective registry (RIETE). The RIETE investigators. J Thromb Haemost 2005;3:703-9.
15. Trujillo-Santos J, Perea-Milla E, Jiménez-Puente A, Sánchez-Cantalejo E, Toro J, Grau E, et al. Bed rest or ambulation in the initial treatment of patients with acute deep vein thrombosis or pulmonary embolism. Findings from the RIETE Registry. The RIETE investigators. Chest 2005;127:1631-6.
16. Barba R, Marco J, Martín-Alvarez H, Rondón P, Fernández-Capitán C, García-Bragado F, et al. The influence of extreme body weight on clinical outcome of patients with venous thrombo-embolism: findings from a prospective registry (RIETE). The RIETE investigators. J Thromb Haemost 2005;3:856-62.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
18. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Metas E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006;367:404-11.
19. Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Clin Geriatr Med 2006;22:17-32.
20. Currie CJ, McEwan P, Emmas C, Morgan CL, Peters JR. Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population. Cirr Med Res Opin 2005;21: 1905-13.
21. Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994;72:191-7.
22. Das SK, Cohen AT, Edmonson RA, Melissari MD, Kakkar W. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996;20:521-7.
23. Lopaciuk S, Bielska-Falda H, Noszczyk W, Bielawiec M, Witkiewicz W, Filipecki S, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999;81:26.
24. Gonzalez-Fajardo J, Arreba W, Castrodeza J, Perez JL, Fernández L, Agundez I, et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep vein thrombosis. J Vasc Surg 1999;30:283-92.
25. Veiga F, Escriba A, Maluenda M, López Rubio M, Margalet I, Lezana A, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep vein thrombosis in the elderly: a randomized trial. Thromb Haemost 2000;84:559-64.
26. Hull R, Pineo G, Mah AF. Long-term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis. Blood 2000;96:449a[abstract].
27. Levine MN. Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer. Cancer Treatment Rev 2002;28:145-9.